EDITORIAL

In this issue

Peter CM van de Kerkhof

Department of Dermatology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

Aspects of dermatological treatment in psoriasis, acne and hydradenitis chronica suppurativa and skin cancer will be highlighted in this issue.

In psoriasis, not only the health care insurance costs but also the out-of-pocket costs are relevant. Costs may differ considerably in different areas of the world. In this issue, the costs in the USA will be presented.

In psoriasis, combination treatment is prescribed to the large majority of patients. We have prescribed combination therapy decades ago, but what is the evidence that these combinations are effective and safe? In this issue, the combination of low-dose cyclosporin with calcipotriol betamethasone will be presented.

Two decades ago, the combination of low-dose cyclosporin and calcipotriol proved to be an excellent combination. Furthermore, the combination of UVB and anti-TNF will be presented.

In acne, treatment with isotretinoin is a time-honoured treatment. Two important practical issues will be dealt with in the present issue: obsessive-compulsive symptoms, depression and anxiety as potential side effects, and the use of oral contraceptives. In hydradenitis chronica suppurativa, the efficacy of infliximab and adalimumab will be compared and contrasted.

Skin cancer rates may be increased in patients using immunosuppressive treatments. The effect of cyclosporin and biological treatments on the occurrence of skin cancers will be presented.